|
 Roche, the world's biggest maker of cancer drugs, said a mid-stage
trial of atezolizumab in people with locally advanced or metastatic
urothelial carcinoma (mUC), showed median overall survival of 11.4
months in people with higher levels of PD-L1 expression and 7.9
months in the overall study population.
It showed that 84 percent of people who responded to atezolizumab
continued to respond regardless of their PD-L1 status when the
results were assessed with longer median follow-up of 11.7 months.
The therapy was well tolerated and adverse events were consistent
with those observed in previous updates, it said.
"It is encouraging to see that the majority of people with advanced
bladder cancer who responded to atezolizumab maintained their
response with longer follow up," said Sandra Horning, Roche's chief
medical officer and head of global product development.
Roche plans to submit the data soon to health authorities and the
U.S. Food and Drug Administration under breakthrough therapy
designation designed to speed the development and review of
medicines that may demonstrate substantial improvement over existing
therapies for serious diseases.
[to top of second column] |
(Reporting by Michael Shields; Editing by Anand Basu)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
